CONFERENCE DAY TWO
7:50 am Light Breakfast & Networking
8:50 am Chair’s Opening Remarks
Uncovering Non-Degrading Molecular Glues to Induce Proximity & Enable Protein-Protein Interactions for Unmet Therapeutic Needs
9:00 am Turbocharging the Discovery of Molecular Glues Ligands for Modulation of Ubiquitin Conjugating Enzymes (E2s)
Synopsis
- Discovery of new chemical space and novel design approach for modulation of Ubiquitin Conjugating Enzymes (E2s)
- Identification of glue-like ligands that enable protein-protein interactions
- Uncovering novel therapeutic opportunities for molecular glues with potential application for treating Proteinopathies
New Company
9:30 am Developing Screening & Rational Design Methods to Identify Cooperative Molecular Glues
Synopsis
- Exploring different experimental approaches for identifying molecular glues
- Specific considerations for characterizing molecular glues in cells
- Case examples for the identification of non-degrading molecular glues
New Data
10:00 am Morning Break & Scientific Poster Session
Synopsis
Contribute to the conversation and share your cutting-edge research with your fellow molecular glue community to showcase your breakthrough discoveries to a vast audience of experts. Register our place to submit an abstract for review to showcase your poster*
*Please visit the website for the T&Cs for presenting a poster
Navigating Lead Optimization to Develop Robust Molecular Glues for Degradation & Beyond
11:00 am Utilizing the TrueGlue Platform: A Systematic & Rational Platform for the Discovery of Molecular Glues
Synopsis
- Advancing precision medicines through rational selection of protein pairs and systematic design of cooperative molecular glues
- Combining the benefits of small molecule drugs with the high specificity of antibodies to address the most challenging targets in a tissue localized manner for use in a range of disease indications
- Showcasing the latest advances to our glue discovery platform and provide updates on our internal portfolio
New Company
11:30 am Extending the Hit Screening Campaign & Lead Optimization Platform to Develop Non-Degrading Molecular Glues
Synopsis
- How to develop diverse libraries to approach on a target
- Exploring topology diversity in the context of medicinal chemistry to identify a novel molecular glue
- Progressing a glue hit from screening to lead optimization
New Data
12:00 pm Panel Discussion: Interrogating the Properties & Characteristics of Molecular Glues to Develop the Most Effective Degraders
Synopsis
- As an industry, how should we define molecular glues going forward to establish great drug discovery and development opportunities that address unmet patient needs?
- What are the ideal properties of molecular glues that small molecules can be optimized towards?
- Where does a molecular glue end and a PROTAC begin?
New Company
1:00 pm Networking Lunch
Improving Pharmacodynamic, Toxicology & PKPD Properties to Streamline Discovery & Development of Safe & Effective Molecular Glues
2:00 pm Utilizing PRISM™ for Intramolecular Glue Design & Optimization to Develop Small Molecules with Reduced Toxicity
Synopsis
- How to identify unique binding pockets in SARM1 as sites for an intramolecular glue
- Predicting toxicology and PKPD of molecular glues with PRISM to streamline development of glues
- Validating the PRISM platform with experimental results to continue predicting molecular glue properties
New Data
New Company
2:30 pm Decoupling of Drug Exposure & Pharmacodynamics as an Opportunity for Spaced Out Dosing Schedules of Molecular Glues
Synopsis
- Exploring the pharmacodynamic effects of glue degraders that persist after drug clearance until the target protein is resynthesized
- Achieving long lasting effects on cellular signaling with short exposures to the degrader
- Spacing out administration of treatment as an option to consider for degrader programs
New Data
3:00 pm Afternoon Networking Break
Spotlighting Clinical Efficacy of Molecular Glues to Fast-Track Effective Therapies to Patients Faster
3:30 pm Roundtable Discussion: Anticipating the Journey of Molecular Glues Through the Clinic & Spearheading Their Market Approval
Synopsis
- What are the future opportunities for molecular glues to receive FDA approval?
- Are there specific regulations for molecular glues?
- Can we reimagine previously used small molecules as molecular glues?
New Company
4:00 pm Driving Forward Molecular Glues – Pre-Clinical & Clinical Data with Lead Molecular Glue Degraders
Synopsis
- Advancing small molecule degraders D7 for TNBC and 433Beta for prostate cancers – tumor regression in animal models
- Uncovering the mechanism of molecular glue induced degradation of Androgen Receptor and MNK1/2
- Showcasing the results from a Phase II human clinical trial in PDAC with a molecular glue
New Company